New use of diphenylbutyl-piperazinecarboxamides in the treatment of substance disorders
CA 2083505 C · Owner: Biovitrum Ab · Inventors: Christensson, Erik; Bjork, Anders
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
New use of certain diphenylbutyl-piperazinecarboxamides especially , amperozide, 4-4,4-bis(4-fluorophenyl)butyl-Nethyl-I-piperazinecarboxamide, and salts thereof in the treatment of , substance abuse disorders. More particularly this treatment, relates to the amelioration of withdrawal symptoms and to modifying drugseeking behaviour.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 23, 1992 and granted June 10, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 23, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 23, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.